Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
AlzeCure Pharma AB (publ) is a pharmaceutical firm focused on pioneering drug treatments for debilitating conditions impacting the central nervous system (CNS). The company's pipeline of potential medicines is rooted in three distinct research platforms: NeuroRestore, Alzstatin, and Painless. Among its experimental compounds, ACD856 is currently in Phase I clinical trials for multiple indications, including Alzheimer's disease, sleep disturbances, traumatic brain injuries, and Parkinson's disease. Furthermore, ACD857, ACD679, and ACD680 are being developed for Alzheimer's treatment. Another candidate, ACD440, a TRPV1 antagonist intended for neuropathic pain, has successfully completed its Phase I clinical assessment. Additionally, TrkA-NAM is in development to alleviate osteoarthritic pain. Founded in 2012, AlzeCure Pharma AB (publ) maintains its headquarters in Huddinge, Sweden.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.